Skip to content

Attovia Therapeutics

US · ATTO #3464 by market cap Listed 2026
15.10 -0.48 -3.08%
Periodic snapshot; not a real-time feed. · 2026-11-20 16:10

Price chart

After-hours 15.10 0.00%
25.5513.7315.102026-08-052026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ATTO?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Neutral
  • Recent price momentum is -25.3% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has risen to 3.5% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bearish
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is below the 60-day average, a short-term downtrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-21 20:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall C

The radar needs all six factors. Available grades are shown below.

Valuation N/A

How expensive the stock is versus earnings, sales and its own 5-year history.

Not enough data to grade this factor.

Growth C-

How fast revenue, profit and free cash flow are compounding.

Revenue CAGR (3Y) -7.3% Better than 9%
Net income CAGR (3Y) -27.7% Better than 12%
Free cash flow CAGR (3Y) 33.2% Better than 76%
Profitability C-

How much profit the business keeps from each dollar of sales and capital.

Gross margin 92.4% Better than 97%
Operating margin -4,974.7% Better than 1%
Net margin -4,511.0% Better than 1%
Return on equity -174.1% Better than 3%
Return on invested capital -5.5% Better than 21%
Momentum D+

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return -27.4% Better than 20%
Distance below 52-week high 46.1% Better than 22%
Financial Health A

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 14.2x Better than 96%
Debt to assets 3.2% Better than 84%
Interest coverage 0.0x Better than 25%
Free cash flow / net income 215.9% Better than 79%
Analyst View A+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 100.0% Better than 77%
Upside to average target 171.5% Better than 92%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -0.20%
1M +7.55%
3M -25.28%

Key statistics

Price & volume

Prev close
15.58
Open
15.40
Day range
14.80 - 15.46
Avg price
15.08
Volume
372.22K
Turnover
5.61M
Amplitude
4.22%
52-week range
12.94 - 28.00

Valuation

P/E
-10.67
P/E (TTM)
-8.74
P/B
1.74
EPS
-1.42
Net profit
-64.68M
Net assets
397.74M

Share structure

Market cap
690.26M
Float cap
256.70M
Shares out
45.71M
Float shares
17.00M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2026-08-05
52-week range 14% of range
12.94 28.00

46.1% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-4.96M net over the window

Short interest

Shares short
1.59M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Attovia Therapeutics (ATTO)?

Attovia Therapeutics last traded at 15.10. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Attovia Therapeutics's market cap?

About 690.26M.

What is the P/E ratio of Attovia Therapeutics?

The trailing twelve-month P/E is -8.74. The Valuation tab shows it against the stock's own five-year range.

Does Attovia Therapeutics pay a dividend?

Attovia Therapeutics does not currently pay a regular dividend.

Is Attovia Therapeutics a buy according to analysts?

The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 41.00, which implies 171.5% upside from the current price. This is not investment advice.

What is Attovia Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Attovia Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 16:10:04 · For reference only, not investment advice and not tailored to your situation.

Attovia Therapeutics discussion 0 comments

Add a comment